Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Ragusa, Marco ^a   Avola, Giuseppe ^b   Angelica, Rosario ^a   Barbagallo, Davide ^a   Guglielmino, Maria R ^a   Duro, Laura R ^a   Majorana, Alessandra ^a   Statello, Luisa ^a   Salito, Loredana ^a   Consoli, Carla ^b   Camuglia, Maria G ^b   Di Pietro, Cinzia ^a   Milone, Giuseppe ^b   Purrello, Michele ^a  

^a Unità di BioMedicina Molecolare Genomica e dei Sistemi Complessi   (Italy)

^b Cattedra di Ematologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CD34 ANTIGEN; DEATH RECEPTOR 3; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; MAFOSFAMIDE; ONCOPROTEIN; PROTEIN BIRC2; PROTEIN BIRC3; PROTEIN BIRC6; PROTEIN BIRC8; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; MESSENGER RNA; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CD34 SELECTION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENOTYPE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA RELAPSE; PATIENT CODING; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ADULT; BONE MARROW CELL; CELL MOTION; COHORT ANALYSIS; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PROSPECTIVE STUDY; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MARROW CELLS; CELL MOVEMENT; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 77954662327     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-377     Document Type: Article

References (52)

1. Mrózek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2006, 169-77.
2. Mrózek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008, 35(4):365-77. 10.1053/j.seminoncol.2008.04.007, 18692687.
3. Chauncey TR. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 2001, 13(1):21-6. 10.1097/00001622-200101000-00005, 11148681.
4. Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol 2001, 13(6):463-9. 10.1097/00001622-200111000-00008, 11673686.
5. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006, 368(9550):1894-907. 10.1016/S0140-6736(06)69780-8, 17126723.
6. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc 2006, 81(2):247-60. 10.4065/81.2.247, 16471082.
7. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14(9):2519-26. 10.1158/1078-0432.CCR-07-2223, 18451212.
8. Li ZW, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006, 20(6):333-42. 10.1016/j.blre.2005.08.003, 16920238.
9. Papayannopoulou T, Scadden DT. Stem-cell ecology and stem cells in motion. Blood 2008, 111(8):3923-30. 10.1182/blood-2007-08-078147, 2288715, 18398055.
10. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 2004, 18(1):1-10. 10.1038/sj.leu.2403173, 14574330.
11. Keating S, Suciu S, de Witte T, Zittoun R, Mandelli F, Belhabri A, Amadori S, Fibbe W, Gallo E, Fillet G, Varet B, Meloni G, Hagemeijer A, Fazi P, Solbu G, Willemze R, , . EORTC Leukemia Group, GIMEMA Leukemia Group The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003, 17:60-67. 10.1038/sj.leu.2402782, 12529661, EORTC Leukemia Group, GIMEMA Leukemia Group.
12. Feller N, Schuurhuis GJ, van der Pol MA, Westra G, Weijers GW, van Stijn A, Huijgens PC, Ossenkoppele GJ. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003, 17:68-75. 10.1038/sj.leu.2402781, 12529662.
13. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood 1998, 92:2322-2333.
14. Rodriguez-Nieto S, Zhivotovsky B. Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment. Current Pharmaceutical Design 2006, 12:4411-4425. 10.2174/138161206779010495, 17168751.
15. Mellor HR, Callaghan R. Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response. Pharmacology 2008, 81:275-300. 10.1159/000115967, 18259091.
16. Di Pietro C, Ragusa M, Barbagallo D, Duro LR, Guglielmino MR, Majorana A, Angelica R, Scalia M, Statello L, Salito L, Tomasello L, Pernagallo S, Valenti S, D'Agostino V, Triberio P, Tandurella I, Palumbo GA, La Cava P, Cafiso V, Bertuccio T, Santagati M, Li Destri G, Lanzafame S, Di Raimondo F, Stefani S, Mishra B, Purrello M. The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. BMC Med Genomics 2009, 2(1):20. 10.1186/1755-8794-2-20, 2683874, 19402918.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-8. 10.1006/meth.2001.1262, 11846609.
18. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34(2):374-8.
19. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13:2498-2504. 10.1101/gr.1239303, 403769, 14597658.
20. Hernandez-Toro J, Prieto C, De las Rivas J. APID2NET: unified interactome graphic analyzer. Bioinformatics 2007, 23(18):2495-7. 10.1093/bioinformatics/btm373, 17644818.
21. Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics 2008, 24(2):282-284. 10.1093/bioinformatics/btm554, 18006545.
22. Brandes U, Erlebach T. Network Analysis 2005, Berlin: Springer Verlag.
23. Mattingly CJ, Rosenstein MC, Davis AP, Colby GT, Forrest JN, Boyer JL. The Comparative Toxicogenomics Database: a cross-species resource for building chemical-gene interaction networks. Toxicol Sci 2006, 92(2):587-95. 10.1093/toxsci/kfl008, 1586111, 16675512.
24. Nagy B, Lundán T, Larramendy ML, Aalto Y, Zhu Y, Niini T, Edgren H, Ferrer A, Vilpo J, Elonen E, Vettenranta K, Franssila K, Knuutila S. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 2003, 120(3):434-41. 10.1046/j.1365-2141.2003.04121.x, 12580957.
25. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, Aldinucci D, Perin V, Serraino D, Babare R, Zagonel V, Gruss HJ, Carbone A, Pinto A. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997, 89(6):2048-59.
26. Lucena-Araujo AR, Panepucci RA, dos Santos GA, Jácomo RH, Santana-Lemos BA, Lima AS, Garcia AB, Araújo AG, Falcão RP, Rego EM. The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity. Br J Haematol 2008, 142(1):74-8. 10.1111/j.1365-2141.2008.07160.x, 18422993.
27. Bonelli P, Petrella A, Rosati A, Romano MF, Lerose R, Pagliuca MG, Amelio T, Festa M, Martire G, Venuta S, Turco MC, Leone A. BAG3 protein regulates stress-induced apoptosis in normal and neoplastic leukocytes. Leukemia 2004, 18(2):358-60. 10.1038/sj.leu.2403219, 14628070.
28. Mercier I, Vuolo M, Madan R, Xue X, Levalley AJ, Ashton AW, Jasmin JF, Czaja MT, Lin EY, Armstrong RC, Pollard JW, Kitsis RN. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance. Cell Death Differ 2005, 12(6):682-6. 10.1038/sj.cdd.4401631, 15861191.
29. Cho D, Kim YI, Kang JS, Hahm E, Yang Y, Kim D, Kim S, Kim YS, Hur D, Park H, Hwang YI, Kim TS, Lee WJ. Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin's Lymphoma Cells. J Clin Immunol 2004, 24(5):553-60. 10.1023/B:JOCI.0000040926.37275.3b, 15359114.
30. Vaziri SA, Grabowski DR, Tabata M, Holmes KA, Sterk J, Takigawa N, Bukowski RM, Ganapathi MK, Ganapathi R. c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis. Anticancer Res 2003, 23(5A):3657-61.
31. Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 2008, 32(11):1684-97. 10.1016/j.leukres.2008.01.016, 2633244, 18339423.
32. Corvaro M, Fuoco C, Wagner M, Cecconi F. Analysis of apoptosome dysregulation in pancreatic cancer and of its role in chemoresistance. Cancer Biol Ther 2007, 6(2):209-17. 10.4161/cbt.6.2.3622, 17224646.
33. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, Johnston PG. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006, 25(6):838-48. 10.1038/sj.onc.1209122, 16247474.
34. Nadal C, Maurel J, Gallego R, Castells A, Longarón R, Marmol M, Sanz S, Molina R, Martin-Richard M, Gascón P. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res 2005, 11(13):4770-4. 10.1158/1078-0432.CCR-04-2119, 16000573.
35. Joy MP, Brock A, Ingber DE, Huang S. High-betweenness proteins in the yeast protein interaction network. J Biomed Biotechnol 2005, 2005(2):96-103. 10.1155/JBB.2005.96, 1184047, 16046814.
36. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005, 14(Suppl 1):35-48. 10.1159/000086183, 16103712.
37. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, (9):665-74. 10.1038/nrc2714, 19693095.
38. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology 2005, 20:349-56. 10.1152/physiol.00025.2005, 16174874.
39. Bociek RG, Armitage JO. Hematopoietic growth factors. CA Cancer J Clin 1996, 46(3):165-84. 10.3322/canjclin.46.3.165, 8646546.
40. Lotem J, Sachs L. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene 2002, 21(21):3284-94. 10.1038/sj.onc.1205319, 12032770.
41. Liongue C, Wright C, Russell AP, Ward AC. Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. Int J Biochem Cell Biol 2009, 41(12):2372-5. 10.1016/j.biocel.2009.08.011, 19699815.
42. Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem 2004, 279(26):26915-21. 10.1074/jbc.M313875200, 15078892.
43. Kotone-Miyahara Y, Yamashita K, Lee KK, Yonehara S, Uchiyama T, Sasada M, Takahashi A. Short-term delay of Fas-stimulated apoptosis by GM-CSF as a result of temporary suppression of FADD recruitment in neutrophils: evidence implicating phosphatidylinositol 3-kinase and MEK1-ERK1/2 pathways downstream of classical protein kinase C. J Leukoc Biol 2004, 76(5):1047-56. 10.1189/jlb.0104048, 15328334.
44. Gu L, Chiang KY, Zhu N, Findley HW, Zhou M. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol 2007, 35(6):957-66. 10.1016/j.exphem.2007.03.007, 17533050.
45. Sachs L, Lotem J. Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy. Blood 1993, (82):15-21.
46. Eisele L, Klein-Hitpass L, Chatzimanolis N, Opalka B, Boes T, Seeber S, Moritz T, Flasshove M. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol 2007, 117(1):8-15. 10.1159/000096854, 17095854.
47. Murayama T, Imoto S, Natazuka T, Chihara K, Matsui T. Proliferative reaction of myelogenous leukemia cells with cytokines G-CSF, GM-CSF, M-CSF, SCF and TPO. Leuk Res 1998, 22(6):557-60. 10.1016/S0145-2126(98)00042-3, 9678722.
48. Inukai T, Sugita K, Iijima K, Goi K, Tezuka T, Kojika S, Kagami K, Mori T, Kinoshita A, Suzuki T, O-Koyama T, Nakazawa S. Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. Leukemia 1998, 12(3):382-9. 10.1038/sj.leu.2400951, 9529133.
49. Seal S, Hockenbery DM, Spaulding EY, Kiem HP, Abbassi N, Deeg HJ. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol 2008, 36(12):1660-72. 10.1016/j.exphem.2008.07.012, 2645417, 18838202.
50. Zang F, Sun B, Zhao X, Niu R, Zhang S, Yu M, Wei X, Zhang L. Critical role for c-FLIP(L) on Fas resistance in colon carcinoma cell line HT-29. Cell Biol Int 2008, 32(3):329-36. 10.1016/j.cellbi.2007.12.002, 18243739.
51. Grimwade D, Du MQ, Langabeer S, Rogers J, Solomon E. Screening for mutations of Bcl10 in leukaemia. Br J Haematol 2000, 109(3):611-5. 10.1046/j.1365-2141.2000.02092.x, 10886211.
52. Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, Yang S, Zhang S, Liu L, Lu M, O'Connor-McCourt M, Purisima EO, Wang E. A map of human cancer signaling. Mol Syst Biol 2007, 3:152. 10.1038/msb4100200, 2174632, 18091723.